Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma [0.03%]
一线免疫检查点抑制剂联合化疗治疗肺肉瘤样癌疗效及安全性的评估
He Du,Xinyu Song,Fengying Wu
He Du
Background: Pulmonary sarcomatoid carcinoma (PSC) represents a rare subtype of non-small cell lung cancer (NSCLC), and it has poor pathologic differentiation, aggressive progression, and early metastasis. Conventional ant...
Clinical Trial
Lung Cancer (Auckland, N.Z.). 2025 Jun 9:16:73-83. DOI:10.2147/LCTT.S494990 2025
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC [0.03%]
LIBRETTO-431：确认塞尔帕替尼对化疗的优越性，以及免疫检查点抑制剂在RET融合阳性晚期NSCLC中缺乏疗效，再次证实NSCLC的独特不吸烟为主分子亚型
Alexandria T M Lee,Sai-Hong Ignatius Ou
Alexandria T M Lee
Selpercatinib, a potent and highly selective RET kinase inhibitor with significant CNS activity, has recently gained US approval for the treatment of NSCLC harboring RET fusions (RET+) based on a large-scale single-arm study. The LIBRETTO-4...
Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834) [0.03%]
艾瑞尼每日一次40毫克优于基于铂的化疗药物治疗少见EGFR突变（G719X，S768I和L861Q）（ACHILLES/TORG1834）
Faustine X Luo,Sai-Hong Ignatius Ou
Faustine X Luo
Afatinib, a second-generation covalent EGFR TKI, has been approved for the treatment of the three "uncommon" EGFR mutations (G719X, S768I, and L861Q) based on one pooled retrospective analysis of three prospective trials (LUX-Lung 2, 3 and ...
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions [0.03%]
蝴蝶展翅——PAPILLON研究：化疗序贯艾伏明塔姆单药治疗EGFR 20号外显子插入突变非小细胞肺癌患者疗效的探索性分析
Dalia Kaakour,Misako Nagasaka
Dalia Kaakour
Epidermal growth factor receptor (EGFR) exon 20 insertions are a rare subtype of EGFR mutations that do not respond to EGFR tyrosine kinase inhibitors developed for sensitizing mutations. In 2021, two drugs, amivantamab and mobocertinib eac...
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? [0.03%]
ⅠB~ⅢA期NSCLC完全切除术后单用帕博利珠单抗辅助治疗适应证的解读：FDA批准PEARLS/KEYNOTE-091研究方案吗？
Misako Nagasaka,Saihong Ignatius Ou
Misako Nagasaka
One of the most recent advancements in NSCLC was the approval of immunotherapy in the adjuvant setting. Both atezolizumab and pembrolizumab have been approved for the use in early stage NSCLC patients post resection. As it broadens the opti...
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer [0.03%]
术前同步放化疗后III期非小细胞肺癌淋巴细胞减少对肿瘤反应及预后的相关性分析
Jared Deck,Marissa Hartley,Mohammad Akhter et al.
Jared Deck et al.
Background: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with...
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC [0.03%]
CheckMate-722：Nivolumab联合化疗在TKI耐药EGFR突变型NSCLC患者中的崛起与陨落
Alexandria T M Lee,Misako Nagasaka
Alexandria T M Lee
The treatment of non-small cell lung cancer (NSCLC) has increasingly been driven by the presence of targetable driver mutations, including epidermal growth factor receptor (EGFR) mutations. Tyrosine receptor inhibitors (TKIs) have subsequen...
It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC [0.03%]
解析ADAURA研究：在EGFR突变型II至IIIA期非小细胞肺癌患者中，目前还不能放弃以铂类为基础的辅助化疗
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Recently, the ADAURA study demonstrated statistically significant improved disease-free survival (DFS) with adjuvant osimertinib in patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring an epidermal growth factor...
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib [0.03%]
ADAURA研究启示：采用辅助奥希替尼时代，是否可以摒弃EGFR突变阳性II-IIIa期NSCLC（含Ib）的以铂类为基础的化疗（伴有RB基因改变者未确定）
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang
Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)-IIIA non-small cell lung cancer (NSCLC). The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated stat...
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study [0.03%]
基于注册表的描述性研究：血清肿瘤标志物动力学作为非小细胞肺癌化疗免疫治疗和单纯免疫治疗维持阶段的预测生物标志物
David Lang,Wolfgang Haslinger,Kaveh Akbari et al.
David Lang et al.
Objective: To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy. ...